Inventor · disambiguated record
Thomas F. Tedder
Also filed as: TEDDER THOMAS · TEDDER THOMAS F
32 granted patents·25 pending applications·718 citations·filing 1989–2023
97Inventor score
Files withUNIV DUKE20DANA FARBER CANCER INST INC16TEDDER THOMAS F10MALLAT ZIAD4DANA FABER CANCER INST INC2
Top patents by PatentIndex Score
57 records- 0196US5849589ACulturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cellsUNIV DUKE·Filed 1996·Granted Dec 15, 1998·258 cites·22 claims
- 0292US5484892AMonoclonal antibodies that block ligand binding to the CD22 receptor in mature B cellsDANA FARBER CANCER INST INC·Filed 1993·Granted Jan 16, 1996·229 cites·5 claims
- 0386US8444973B2Anti-CD19 antibodies and uses in B cell disordersTEDDER THOMAS F·Filed 2010·Granted May 21, 2013·7 cites·16 claims
- 0485US10017739B2Methods of expanding and assessing B cells and using expanded B cells to treat diseaseUNIV DUKE·Filed 2013·Granted Jul 10, 2018·12 cites·18 claims
- 0582US10611999B2Methods of expanding and assessing B cells and using expanded B cells to treat diseaseUNIV DUKE·Filed 2018·Granted Apr 7, 2020·2 cites·10 claims
- 0682US9260530B2Anti-CD19 antibodies and uses in B cell disordersUNIV DUKE·Filed 2013·Granted Feb 16, 2016·3 cites·21 claims
- 0780US8734792B2Reagents and treatment methods for autoimmune diseasesTEDDER THOMAS F·Filed 2012·Granted May 27, 2014·3 cites·19 claims
- 0878US2024026346A1Antigen display system and methods for characterizing antibody responsesUNIV DUKE·Filed 2023·Application pending·0 cites
- 0977US11230598B2Antibodies and methods for depleting regulatory bio cells and use in combination with immune checkpoint inhibitorsUNIV DUKE·Filed 2019·Granted Jan 25, 2022·3 cites·20 claims
- 1076US5316920ALymphocyte activation antigen HB15, a member of the immunoglobulin superfamilyDANA FABER CANCER INST INC·Filed 1992·Granted May 31, 1994·33 cites·14 claims
- 1174US9416187B2CD-20 specific antibodies and methods of employing sameTEDDER THOMAS F·Filed 2004·Granted Aug 16, 2016·9 cites·13 claims
- 1274US6068984AAntibodies to lymphocyte activation antigens and uses thereforDANA FARBER CANCER INST INC·Filed 1998·Granted May 30, 2000·20 cites·6 claims
- 1374US2024011015A1Antigen display system and methods for characterizing antibody responsesUNIV DUKE·Filed 2022·Application pending·0 cites
- 1470US5766570ALymphocyte activation antigens and antibodies theretoDANA FARBER CANCER INST INC·Filed 1995·Granted Jun 16, 1998·22 cites·8 claims
- 1570US2023295562A1Regulatory b cells and their usesUNIV DUKE·Filed 2023·Application pending·0 cites
- 1668US5710262ANucleic acid encoding HB15 polypeptidesDANA FABER CANCER INST INC·Filed 1994·Granted Jan 20, 1998·17 cites·3 claims
- 1767US9669057B2Regulatory B cells and their usesTEDDER THOMAS F·Filed 2009·Granted Jun 6, 2017·1 cites·15 claims
- 1866US12144859B2B cell depleting agent for the treatment of atherosclerosisMALLAT ZIAD·Filed 2020·Granted Nov 19, 2024·0 cites·10 claims
- 1966US5808025AChimeric selectins as simultaneous blocking agents for component selectin functionDANA FARBER CANCER INST INC·Filed 1994·Granted Sep 15, 1998·21 cites·14 claims
- 2063US2008118505A1Reagents and treatment methods for autoimmune diseasesUNIV DUKE·Filed 2007·Application pending·0 cites
- 2162US2006280738A1Anti-CD19 antibody therapy for transplantationTEDDER THOMAS F·Filed 2006·Application pending·0 cites
- 2261US5834425AUse of chimeric selectins as simultaneous blocking agents for component selectin functionDANA FARBER CANCER INST INC·Filed 1995·Granted Nov 10, 1998·23 cites·8 claims
- 2360US2009246195A1Anti-cd19 antibody therapy for transplantationUNIV DUKE·Filed 2008·Application pending·0 cites
- 2460US2019136185A1Regulatory b cells and their usesUNIV DUKE·Filed 2018·Application pending·0 cites
- 2559US6921846B1Antibody production methods relating to disruption of peripheral tolerance in B lympho-cytesUNIV DUKE·Filed 1998·Granted Jul 26, 2005·9 cites·2 claims
- 2658US2020239872A1Antigen display system and methods for characterizing antibody responsesUNIV DUKE·Filed 2018·Application pending·0 cites
- 2758US2020283727A1Methods of expanding and assessing b cells and using expanded b cells to treat diseaseUNIV DUKE·Filed 2020·Application pending·0 cites
- 2857US9814740B2Methods and compositions combining immunotherapy with monocyte activationTEDDER THOMAS·Filed 2011·Granted Nov 14, 2017·1 cites·8 claims
- 2957US2019365890A1A B Cell Depleting Agent for the Treatment of AtherosclerosisMALLAT ZIAD·Filed 2019·Application pending·0 cites
- 3057US2013084294A1Anti-cd19 antibodies and uses in b cell disordersTEDDER THOMAS F·Filed 2012·Application pending·0 cites
- 3156US2003202975A1Reagents and treatment methods for autoimmune diseasesFiled 2003·Application pending·0 cites
- 3256US2013224215A1A B Cell Depleting Agent for the Treatment of AtherosclerosisMALLAT ZIAD·Filed 2013·Application pending·0 cites
- 3355US2009285808A1Anti-cd19 antibodies and uses in oncologyUNIV DUKE·Filed 2009·Application pending·0 cites
- 3455US2010158901A1Anti-cd19 antibody therapy for autoimmune diseaseUNIV DUKE·Filed 2008·Application pending·0 cites
- 3554US2004137566A1Identification of novel ms4a gene family members expressed by hematopoietic cellsFiled 2001·Application pending·0 cites
- 3654US2007264260A1Treatment methods using anti-CD22 antibodiesUNIV CALIFORNIA·Filed 2006·Application pending·0 cites
- 3753US4987084AMethod of testing the effect of a molecule on B lymphocyte functionDANA FARBER CANCER INST INC·Filed 1989·Granted Jan 22, 1991·14 cites·8 claims
- 3851US2006021069A1Antibody production methods related to disruption of peripheral tolerance in B lymphocytesTEDDER THOMAS F·Filed 2005·Application pending·0 cites
- 3951US2006134751A1Identification of novel MS4A gene family members expressed by hematopoietic cellsTEDDER THOMAS F·Filed 2006·Application pending·0 cites
- 4050US10131875B2Regulatory B cells and their usesTEDDER THOMAS F·Filed 2011·Granted Nov 20, 2018·0 cites·8 claims
- 4150US6020152ALymphocyte-associated cell surface proteinDANA FARBER CANCER INST INC·Filed 1993·Granted Feb 1, 2000·5 cites·8 claims
- 4248US5389520ASpecific detection of cell surface receptor leukocyte adhesion molecule-1DANA FARBER CANCER INST INC·Filed 1992·Granted Feb 14, 1995·7 cites·6 claims
- 4347US5831142ARegulatory elements controlling tissue-specific gene expressionDANA FARBER CANCER INST INC·Filed 1994·Granted Nov 3, 1998·12 cites·1 claims
- 4447US2006233791A1Anti-CD19 antibodies and uses in oncologyUNIV DUKE·Filed 2006·Application pending·0 cites
- 4547US2006263357A1Anti-CD19 antibody therapy for autoimmune diseaseTEDDER THOMAS F·Filed 2006·Application pending·0 cites
- 4646US9913863B2Regulatory B cells and their usesUNIV DUKE·Filed 2016·Granted Mar 13, 2018·0 cites·20 claims
- 4746US2011275791A1A B Cell Depleting Agent for the Treatment of AtherosclerosisMALLAT ZIAD·Filed 2010·Application pending·0 cites
- 4846US2004001828A1Treatment methods using anti-CD22 antibodiesFiled 2003·Application pending·0 cites
- 4941US2017088625A1Cd-20-specific antibodies and methods of employing sameUNIV DUKE·Filed 2016·Application pending·0 cites
- 5039US5776775AAnti-LAM 1-3 antibody and hybridomaDANA FARBER CANCER INST INC·Filed 1994·Granted Jul 7, 1998·3 cites·5 claims
Showing the top 50 of 57 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Thomas F. Tedder files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →